Stress-Testing US Colorectal Cancer Screening Guidelines: Decennial Colonoscopy from Age 45 is Robust to Natural History Uncertainty and Colonoscopy Sensitivity Assumptions
- PMID: 40302197
- PMCID: PMC12167147
- DOI: 10.1177/0272989X251334373
Stress-Testing US Colorectal Cancer Screening Guidelines: Decennial Colonoscopy from Age 45 is Robust to Natural History Uncertainty and Colonoscopy Sensitivity Assumptions
Abstract
PurposeThe 2023 American College of Physicians (ACP) guidelines for colorectal cancer (CRC) screening are at odds with the United States Preventive Task Force (USPSTF) guidelines, with the former recommending screening starting at age 50 y and the latter at age 45 y. This article "stress tests" CRC colonoscopy screening strategies to investigate their robustness to uncertainties stemming from the natural history of disease and sensitivity of colonoscopy.MethodsThis study uses the CRC-SPIN microsimulation model to project the life-years gained (LYG) under several colonoscopy CRC screening strategies. The model was extended to include birth cohort effects on adenoma risk. We estimated natural history parameters under 2 different assumptions about the youngest age of adenoma initiation. For each, we generated 500 parameter sets to reflect uncertainty in the natural history parameters. We simulated 26 colonoscopy screening strategies and examined 4 different colonoscopy sensitivity assumptions, encompassing the range of sensitivities consistent with prior tandem colonoscopy studies. Across this set of scenarios, we identify efficient screening strategies and report posterior credible intervals for benefits of screening (LYG), burden (number of colonoscopies), and incremental burden-effectiveness ratios.ResultsProjected absolute screening benefits varied widely based on assumptions, but strategies starting at age 45 y were consistently in the efficiency frontier. Strategies in which screening starts at age 50 y with 10-y intervals were never efficient, saving fewer life-years than starting screening at age 45 y and performing colonoscopies every 15 y while requiring more colonoscopies per person.ConclusionsDecennial colonoscopy screening initiation at age 45 y remained a robust recommendation. Colonoscopy screening with a 10-y interval starting at age 50 y did not result in an efficient use of colonoscopies in any of the scenarios evaluated.HighlightsColorectal cancer colonoscopy screening strategies initiated at age 45 y were projected to yield more life-years gained while requiring the least number of colonoscopies across different model assumptions about disease natural history and colonoscopy sensitivity.Colonoscopy screening starting at age 50 y with a 10-y interval consistently underperformed strategies that started at age 45 y.
Keywords: cancer screening; colorectal cancer; robust decision making.
Conflict of interest statement
The authors declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article. The authors disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This research was supported by grant U01-CA253913 from the National Cancer Institute as part of the Cancer Intervention and Surveillance Modeling Network (CISNET). Its contents are solely the responsibility of the authors and do not necessarily represent the official views of the National Cancer Institute. This work was also supported by a Rothenberg Dissertation Award provided by the Pardee RAND Graduate School. The funding agreement ensured the authors’ independence in designing the study, interpreting the data, writing, and publishing the report. This research used resources of the Argonne Leadership Computing Facility, which is a DOE Office of Science User Facility supported under contract DE-AC0206CH11357. This research was completed with resources provided by the Laboratory Computing Resource Center at Argonne National Laboratory.
Figures



Similar articles
-
A rapid and systematic review of the clinical effectiveness and cost-effectiveness of paclitaxel, docetaxel, gemcitabine and vinorelbine in non-small-cell lung cancer.Health Technol Assess. 2001;5(32):1-195. doi: 10.3310/hta5320. Health Technol Assess. 2001. PMID: 12065068
-
Optimal Stopping Ages for Colorectal Cancer Screening.JAMA Netw Open. 2024 Dec 2;7(12):e2451715. doi: 10.1001/jamanetworkopen.2024.51715. JAMA Netw Open. 2024. PMID: 39699893 Free PMC article.
-
Chemoprevention of colorectal cancer: systematic review and economic evaluation.Health Technol Assess. 2010 Jun;14(32):1-206. doi: 10.3310/hta14320. Health Technol Assess. 2010. PMID: 20594533
-
Signs and symptoms to determine if a patient presenting in primary care or hospital outpatient settings has COVID-19.Cochrane Database Syst Rev. 2022 May 20;5(5):CD013665. doi: 10.1002/14651858.CD013665.pub3. Cochrane Database Syst Rev. 2022. PMID: 35593186 Free PMC article.
-
Surveillance of Barrett's oesophagus: exploring the uncertainty through systematic review, expert workshop and economic modelling.Health Technol Assess. 2006 Mar;10(8):1-142, iii-iv. doi: 10.3310/hta10080. Health Technol Assess. 2006. PMID: 16545207
References
-
- Siegel RL, Wagle NS, Cercek A, Smith RA, Jemal A. Colorectal cancer statistics, 2023. CA Cancer J Clin. 2023;73(3):233–54. Available from: DOI: 10.3322/caac.21772; https://acsjournals.onlinelibrary.wiley.com/doi/10.3322/caac.21772 - DOI - DOI - PubMed
-
- National Cancer Institute. SEER Explorer—long term trends, 2021. Available from: https://seer.cancer.gov/explorer/application.html?site=20&data_type=2&gr...
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Medical